This website is intended for healthcare professionals only.

Newsletter      
Hospital Healthcare Europe
HOPE LOGO
Hospital Healthcare Europe

Increased infection rates are associated with use of invasive devices, in particular, central lines, urinary catheters, and ventilators.1 15-38% of patients receive haemodialysis using a central venous catheter (CVC) in European countries.2

ClearGuardTM HD caps are clinically proven to reduce the rate of bloodstream infections in haemodialysis catheters.3

To celebrate the European launch of this innovative piece of medical technology, ICU Medical has produced a series of country-specific presentations featuring local renal specialists who share their experience with ClearGuardTM HD.

German Webinar

Prof. Dr. Martin Kuhlmann, Director of the Department of Nephrology at Vivantes-International, presents an in-depth look at the use of ClearGuardTM HD in his hospital. He is joined by ICU Medical’s Lucia Vitale who shares manufacturer’s insights and Dr. Steven Brunelli from Davita Clinical Research who presents data from an innovative clinical study.

Spanish Webinar

Dr. Fernando Henríquez Palop, Head of the Department of Nephrology at Avericum Dialysis centre, details key perspectives on the performance of ClearGuardTM HD in his centre. He is joined by ICU Medical’s Roberto Zambrano who shares manufacturer’s insights and Dr. Steven Brunelli from Davita Clinical Research who presents data from an innovative clinical study.

French Webinar

Dr. Mohamed Belmouaz, Consultant at the CHU Poitiers Nephrology and Renal Transplantation Unit, presents a detailed account of his experience of using ClearGuardTM HD in his hospital. He is joined by ICU Medical’s Arnaud Cazanobe who shares manufacturer’s insights and Dr. Steven Brunelli from Davita Clinical Research who presents data from an innovative clinical study.

UK Webinar

In celebration of the recent publication of the UK’s NICE National Guidance for preventing haemodialysis catheter-related bloodstream infections, ClearGuardTM HD has been officially recommended in the prestigious medical technology guidance [MTG62]. Dr Marlies Ostermann, Consultant in Nephrology and Critical Care at Guy’s and St Thomas’, presents the guidance highlights. She is joined by ICU Medical’s Jason Battle​ who shares manufacturer’s insights and Dr. Steven Brunelli from Davita Clinical Research who presents data from an innovative clinical study.

References

  1. Report on the Burden of Endemic Health Care-Associated Infection Worldwide, World Health Organization. 2011.
  2. Pisoni, RL et al. Trends in US Vascular Access Use, Patient Preferences, and Related Practices: An Update From the US DOPPS Practice Monitor With International Comparisons.Am J Kidney Dis. 2015
  3. Brunelli, SM et al. Cluster-randomized trial of devices to prevent catheter-related bloodstream infection. J Am Soc Nephrol. 2018 Apr,29(4):1336-1343.

The product complies with current legislation and has the corresponding CE marking. For additional information, warnings and /or safety precautions, refer to the manufacturer’s Instructions for Use.

This content is sponsored by ICU Medical